Neoplasm Recurrence, Local

"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

Descriptor ID	D009364
MeSH Number(s)	C04.697.655 C23.550.727.655
Concept/Terms	Neoplasm Recurrence, Local Neoplasm Recurrence, Local Local Neoplasm Recurrences Locoregional Neoplasm Recurrence Recurrences, Local Neoplasm Neoplasm Recurrences, Local Recurrence, Local Neoplasm Recurrence, Locoregional Neoplasm Local Neoplasm Recurrence Neoplasm Recurrence, Locoregional Locoregional Neoplasm Recurrences Neoplasm Recurrences, Locoregional Recurrences, Locoregional Neoplasm

Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".

Diseases [C]
Neoplasms [C04]
Neoplastic Processes [C04.697]
Neoplasm Recurrence, Local [C04.697.655]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Neoplastic Processes [C23.550.727]
Neoplasm Recurrence, Local [C23.550.727.655]

Below are MeSH descriptors whose meaning is related to "Neoplasm Recurrence, Local".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.

Bar chart showing 283 publications over 30 distinct years, with a maximum of 26 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	0	1	1
1997	0	1	1
1998	0	2	2
2000	0	1	1
2001	0	1	1
2002	1	2	3
2003	0	1	1
2004	2	3	5
2005	1	2	3
2006	2	3	5
2007	2	3	5
2008	3	3	6
2009	4	4	8
2010	3	8	11
2011	6	8	14
2012	5	7	12
2013	13	1	14
2014	11	7	18
2015	9	3	12
2016	9	2	11
2017	7	7	14
2018	9	8	17
2019	4	9	13
2020	4	14	18
2021	5	20	25
2022	1	25	26
2023	0	17	17
2024	7	6	13
2025	2	3	5

Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Sep; 43(25):2766-2771.

View in: PubMed
Freitas AJA, Causin RL, Calfa S, Santana IVV, Balie M, Hirai W, Laus AC, Araujo HS, Hidalgo Filho CM, de Oliveira Bombarda F, da Silva VD, Evangelista AF, de P?dua Souza C, Reis RM, Marques MMC. Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes. Breast Cancer Res Treat. 2025 Jul; 212(2):237-250.

View in: PubMed
Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, Denschlag D, Myers T, Thijs AM, Pennington KP, Gilbert L, Fleming E, Zub O, Landrum LM, Ataseven B, Gogoi R, Podzielinski I, Cloven N, Monk BJ, Sharma S, Herzog TJ, Stuckey A, Pothuri B, Secord AA, Chase D, Vincent V, Meyers O, Garside J, Mirza MR, Black D. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial. Int J Gynecol Cancer. 2025 Jun; 35(6):101852.

View in: PubMed
Takami H, Matsutani M, Suzuki T, Takabatake K, Fujimaki T, Okamoto M, Yamaguchi S, Kanamori M, Matsuda K, Sonoda Y, Natsumeda M, Ichinose T, Nakada M, Muroi A, Ishikawa E, Takahashi M, Narita Y, Tanaka S, Saito N, Higuchi F, Shin M, Mineharu Y, Arakawa Y, Kagawa N, Kawabata S, Wanibuchi M, Takayasu T, Yamasaki F, Fujii K, Ishida J, Date I, Miyake K, Fujioka Y, Kuga D, Yamashita S, Takeshima H, Shinojima N, Mukasa A, Asai A, Nishikawa R. Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study. Neuro Oncol. 2025 Mar 07; 27(3):828-840.

View in: PubMed
Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L, Talpes M, Majer I, Patel S, Usmani SZ. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial. Clin Lymphoma Myeloma Leuk. 2025 Aug; 25(8):590-605.

View in: PubMed
Tringale KR, Scordo M, Yahalom J, White C, Zhang Z, Vachha B, Cederquist G, Schaff L, DeAngelis L, Grommes C, Imber BS. Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro Oncol. 2024 Nov 04; 26(11):2061-2073.

View in: PubMed
Bennett FJ, Keilson JM, Turgeon MK, Oppat KM, Warren EAK, Shah SA, Agopian VG, Magliocca JF, Cameron A, Orloff SL, Kubal CA, Cannon RM, Akoad ME, Emamaullee J, Aucejo F, Vagefi PA, Nguyen MH, Dhanireddy K, Kazimi MM, Sonnenday CJ, Foley DP, Abdouljoud M, Sudan DL, Humar A, Doyle MBM, Chapman WC, Maithel SK. Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma. Ann Surg Oncol. 2025 Jan; 32(1):426-437.

View in: PubMed
Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.

View in: PubMed
Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.

View in: PubMed
Liu GY, Ye YF, Jiang YF, Chen GJ, Xia WX, Huang YS, Gao TS, Liu YM, Hou YT, Li JF, Liu JH, Lu N, Chen CL, Ke LR, Liang H, Bei WX, Li WZ, Dong SH, Liu Q, Xie C, Yao HR, Xiang YQ. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ. 2024 06 19; 385:e077890.

View in: PubMed

People

Explore

Similar Concepts

Top Journals